“This strategic acquisition represents an acceleration of our mission to offer people around the world a better path to wellness and a healthy vibrant life, while also serving as a natural expansion of our Activation philosophy,” said Steve Fife, president and CEO, LifeVantage Corporation shared in a press release,
Under the terms of the definitive agreement, LifeVantage will acquire LoveBiome’s core operating assets. The acquisition is expected to close by mid-October, subject to customary regulatory approvals.
Financial details of the LoveBiome acquisition were not disclosed.
Cross-category expansion: From cellular to gut activation
Known for its cellular health products centered on Nrf2 activation, LifeVantage said the LoveBiome acquisition strengthens its offering with a new angle on microbiome support.
“By bringing LoveBiome products, specifically P84 into our portfolio, we add another powerful activation story with strong synergies to cellular health,” Fife told NutraIngredients. “Gut health plays a foundational role in overall well-being and impacts areas such as weight management, stress and skin health.”
LoveBiome’s P84 is formulated to regulate, repair and restore the microbiome through a science-based approach to gut activation.
“P84 strengthens Activation in the gut and microbiome, a category growing thanks to emerging science and data supporting the gut’s impact on many areas of whole-body health and wellness,” Kelly Olsen, founder and CEO of LoveBiome, said in the press release.
Fife added that the companies are aligned in approach, noting that by combining LoveBiome’s innovative microbiome solutions with LifeVantage’s proven activation technologies, the two are “able to activate wellness, both financial and physical, to a broader base of consumers.”
Consultant reach and infrastructure investment
The acquisition also brings a strategic boost to LifeVantage’s Consultant network, particularly in key markets such as the United States, Taiwan and Europe.
“We see tremendous opportunities to create value on both the business and wellness sides of our mission,” Fife said. “The integration of products like P84 will allow our consultants to expand their reach, helping more people achieve their health goals while also building thriving businesses.”
Recent infrastructure initiatives also played a crucial role in facilitating the acquisition.
“The timing of this strategic acquisition is a testament to the transformational work LifeVantage has been delivering the past three years,” Fife said. “The success of LifeVantage’s compensation plan, product and digital LV360 initiatives laid the foundation that now allows for investment into the core business to leverage our platform and accelerate growth.”
According to the company, Olsen and other key LoveBiome personnel will join LifeVantage post-acquisition to ensure continuity and strengthen integration across the direct sales channel.
High-growth categories with long-term tailwinds
LifeVantage positioned the acquisition as part of its broader strategy to lead in two of the fastest-growing areas in the global wellness market.
“Cellular and gut health are two of the fastest-growing areas in wellness,” Fife said. “With this momentum, LifeVantage is well-positioned to lead in both categories.”
The company cited projections that the global gut health supplement market is expected to grow from $14.4 billion in 2025 to $32.4 billion by 2035, representing a compound annual growth rate of 8.4%.
“We are excited to join forces with LifeVantage and help entrepreneurs around the world love life with the very best compensation plan, products and community in the industry,” Olsen said.
